

Kunwei Shen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3335053/publications.pdf>

Version: 2024-02-01

103
papers

2,489
citations

430874

18
h-index

223800

46
g-index

113
all docs

113
docs citations

113
times ranked

3921
citing authors

#	ARTICLE	IF	CITATIONS
1	Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 580-591.	10.7	434
2	The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2016, 11, e0152500.	2.5	219
3	Breast Cancer: Diffusion Kurtosis MR Imaging's Diagnostic Accuracy and Correlation with Clinical-Pathologic Factors. <i>Radiology</i> , 2015, 277, 46-55.	7.3	196
4	Modulation of M2 macrophage polarization by the crosstalk between Stat6 and Trim24. <i>Nature Communications</i> , 2019, 10, 4353.	12.8	193
5	The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e115103.	2.5	182
6	Single-cell RNA sequencing in breast cancer: Understanding tumor heterogeneity and paving roads to individualized therapy. <i>Cancer Communications</i> , 2020, 40, 329-344.	9.2	110
7	A novel long non-coding RNA-ARA: Adriamycin Resistance Associated. <i>Biochemical Pharmacology</i> , 2014, 87, 254-283.	4.4	100
8	Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia. <i>JAMA Oncology</i> , 2020, 6, e193692.	7.1	94
9	Combined niclosamide with cisplatin inhibits epithelial-mesenchymal transition and tumor growth in cisplatin-resistant triple-negative breast cancer. <i>Tumor Biology</i> , 2016, 37, 9825-9835.	1.8	52
10	Metabolic Syndrome and Breast Cancer: Prevalence, Treatment Response, and Prognosis. <i>Frontiers in Oncology</i> , 2021, 11, 629666.	2.8	43
11	Breast Subtypes and Prognosis of Breast Cancer Patients With Initial Bone Metastasis: A Population-Based Study. <i>Frontiers in Oncology</i> , 2020, 10, 580112.	2.8	37
12	Adipocytes promote breast tumorigenesis through TAZ-dependent secretion of Resistin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 33295-33304.	7.1	37
13	Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients. <i>BMC Cancer</i> , 2015, 15, 822.	2.6	34
14	Elevated preoperative neutrophil-to-lymphocyte ratio predicts poor disease-free survival in Chinese women with breast cancer. <i>Tumor Biology</i> , 2016, 37, 4135-4142.	1.8	34
15	Biologic behavior and long-term outcomes of breast ductal carcinoma <i>in situ</i> with microinvasion. <i>Oncotarget</i> , 2016, 7, 64182-64190.	1.8	34
16	Prognostic and predictive value of Ki-67 in triple-negative breast cancer. <i>Oncotarget</i> , 2016, 7, 31079-31087.	1.8	34
17	Distribution patterns of 21-gene recurrence score in 980 Chinese estrogen receptor-positive, HER2-negative early breast cancer patients. <i>Oncotarget</i> , 2017, 8, 38706-38716.	1.8	31
18	Niclosamide inhibits epithelial-mesenchymal transition and tumor growth in lapatinib-resistant human epidermal growth factor receptor 2-positive breast cancer. <i>International Journal of Biochemistry and Cell Biology</i> , 2016, 71, 12-23.	2.8	22

#	ARTICLE	IF	CITATIONS
19	Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 1877-1886.	2.5	21
20	Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?. <i>European Journal of Cancer</i> , 2018, 89, 9-18.	2.8	20
21	Higher axillary lymph node metastasis burden in breast cancer patients with positive preoperative node biopsy: may not be appropriate to receive sentinel lymph node biopsy in the post-ACOSOG Z0011 trial era. <i>World Journal of Surgical Oncology</i> , 2019, 17, 37.	1.9	18
22	A large-cohort retrospective study of metastatic patterns and prognostic outcomes between inflammatory and non-inflammatory breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592093267.	3.2	18
23	The impact of surgical excision of the primary tumor in stage IV breast cancer on survival: a meta-analysis. <i>Oncotarget</i> , 2018, 9, 11816-11823.	1.8	17
24	A Long Noncoding RNA Signature That Predicts Pathological Complete Remission Rate Sensitively in Neoadjuvant Treatment of Breast Cancer. <i>Translational Oncology</i> , 2017, 10, 988-997.	3.7	16
25	Impact of Prior Cancer History on the Clinical Outcomes in Advanced Breast Cancer: A Propensity Score-Adjusted, Population-Based Study. <i>Cancer Research and Treatment</i> , 2020, 52, 552-562.	3.0	16
26	Subdivision of M1 Stage for De Novo Metastatic Breast Cancer to Better Predict Prognosis and Response to Primary Tumor Surgery. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 1521-1528.	4.9	16
27	Fulvestrant 500 mg vs 250 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer: a randomized, double-blind registrational trial in China. <i>Oncotarget</i> , 2016, 7, 57301-57309.	1.8	15
28	Danggui Buxue Decoction, a Classical Formula of Traditional Chinese Medicine, Fails to Prevent Myelosuppression in Breast Cancer Patients Treated With Adjuvant Chemotherapy: A Prospective Study. <i>Integrative Cancer Therapies</i> , 2017, 16, 406-413.	2.0	14
29	Prolonged Time to Adjuvant Chemotherapy Initiation Was Associated with Worse Disease Outcome in Triple Negative Breast Cancer Patients. <i>Scientific Reports</i> , 2020, 10, 7029.	3.3	14
30	BFAR coordinates TGF β 2 signaling to modulate Th9-mediated cancer immunotherapy. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	14
31	21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes. <i>Scientific Reports</i> , 2019, 9, 13123.	3.3	13
32	<p>A high absolute lymphocyte count predicts a poor prognosis in HER-2- positive breast cancer patients treated with trastuzumab</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 3371-3379.	1.9	13
33	Clinicopathological Features and Disease Outcome in Breast Cancer Patients with Hormonal Receptor Discordance between Core Needle Biopsy and Following Surgical Sample. <i>Annals of Surgical Oncology</i> , 2019, 26, 2779-2786.	1.5	13
34	A prospective, randomized study of Toremifene vs. tamoxifen for the treatment of premenopausal breast cancer: safety and genital symptom analysis. <i>BMC Cancer</i> , 2020, 20, 663.	2.6	13
35	A Smartphone-Based App to Improve Adjuvant Treatment Adherence to Multidisciplinary Decisions in Patients With Early-Stage Breast Cancer: Observational Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e27576.	4.3	13
36	Association of tumor-infiltrating lymphocytes before and after neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. <i>Cancer Medicine</i> , 2021, 10, 7921-7933.	2.8	12

#	ARTICLE	IF	CITATIONS
37	Axillary lymph node and non-sentinel lymph node metastasis among the ACOSOG Z0011 eligible breast cancer patients with invasive ductal, invasive lobular, or other histological special types: a multi-institutional retrospective analysis. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 193-202.	2.5	11
38	Compliance with multidisciplinary team recommendations and disease outcomes in early breast cancer patients: An analysis of 4501 consecutive patients. <i>Breast</i> , 2020, 52, 135-145.	2.2	11
39	IGF-1 Interacted With Obesity in Prognosis Prediction in HER2-Positive Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 550.	2.8	11
40	Identification of a novel immune-related prognostic signature associated with tumor microenvironment for breast cancer. <i>International Immunopharmacology</i> , 2021, 100, 108122.	3.8	11
41	Weight Gain during Neoadjuvant Chemotherapy is Associated with Worse Outcome among the Patients with Operable Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 399.	1.9	10
42	Predictors for Survival and Distribution of 21-Gene Recurrence Score in Patients With Pure Mucinous Breast Cancer: A SEER Population-Based Retrospective Analysis. <i>Clinical Breast Cancer</i> , 2019, 19, e66-e73.	2.4	10
43	HER2 positivity is not associated with adverse prognosis in high-risk estrogen receptor-positive early breast cancer patients treated with chemotherapy and trastuzumab. <i>Breast</i> , 2020, 54, 235-241.	2.2	10
44	Comprehensive Transcriptomic Analysis Reveals Dysregulated Competing Endogenous RNA Network in Endocrine Resistant Breast Cancer Cells. <i>Frontiers in Oncology</i> , 2020, 10, 600487.	2.8	10
45	A Decision Support System with Intelligent Recommendation for Multi-disciplinary Medical Treatment. <i>ACM Transactions on Multimedia Computing, Communications and Applications</i> , 2020, 16, 1-23.	4.3	10
46	Concurrent adjuvant radiochemotherapy versus standard chemotherapy followed by radiotherapy in operable breast cancer after breast conserving therapy: A meta-analysis. <i>Journal of Cancer Research and Therapeutics</i> , 2016, 12, 84.	0.9	10
47	Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study. <i>Journal of Cancer</i> , 2018, 9, 3216-3224.	2.5	9
48	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer. <i>Journal of Cancer</i> , 2019, 10, 1110-1116.	2.5	9
49	Inhibition of the FACT Complex Targets Aberrant Hedgehog Signaling and Overcomes Resistance to Smoothed Antagonists. <i>Cancer Research</i> , 2021, 81, 3105-3120.	0.9	9
50	Association of Biomarker Discrepancy and Treatment Decision, Disease Outcome in Recurrent/Metastatic Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 638619.	2.8	9
51	Diffusion-Weighted Imaging-guided MR Spectroscopy in Breast Lesions using Readout-Segmented Echo-Planar Imaging. <i>European Radiology</i> , 2016, 26, 1565-1574.	4.5	8
52	Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis. <i>Journal of Cancer</i> , 2020, 11, 6916-6924.	2.5	8
53	Association between tumor molecular subtype, clinical stage and axillary pathological response in breast cancer patients undergoing complete pathological remission after neoadjuvant chemotherapy: potential implications for de-escalation of axillary surgery. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199667.	3.2	8
54	Association of molecular subtype concordance and survival outcome in synchronous and metachronous bilateral breast cancer. <i>Breast</i> , 2021, 57, 71-79.	2.2	8

#	ARTICLE	IF	CITATIONS
55	CHD1L promotes cell cycle progression and cell motility by up-regulating MDM2 in breast cancer. American Journal of Translational Research (discontinued), 2019, 11, 1581-1592.	0.0	8
56	Long Noncoding RNA Signature and Disease Outcome in Estrogen Receptor-Positive Breast Cancer Patients Treated with Tamoxifen. Journal of Breast Cancer, 2018, 21, 277.	1.9	7
57	Associations Between Circulating Insulin-Like Growth Factor 1 and Mortality in Women With Invasive Breast Cancer. Frontiers in Oncology, 2020, 10, 1384.	2.8	7
58	A novel metabolic gene signature-based nomogram to predict overall survival in breast cancer. Annals of Translational Medicine, 2021, 9, 367-367.	1.7	7
59	A771726, an anti-inflammatory drug, exerts an anticancer effect and reverses tamoxifen resistance in endocrine-resistant breast cancer cells. Oncology Reports, 2014, 32, 627-634.	2.6	6
60	Can Clinically Node-Negative Breast Cancer Patients with Suspicious Axillary Lymph Nodes at Ultrasound But Negative Fine-Needle Aspiration Be Approached as Having Node-Negative Disease?. Annals of Surgical Oncology, 2017, 24, 1874-1880.	1.5	6
61	4-Hydroxytamoxifen enhances sensitivity of estrogen receptor \pm -positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion. Breast Cancer Research and Treatment, 2019, 175, 567-578.	2.5	6
62	Association of sonographic features and molecular subtypes in predicting breast cancer disease outcomes. Cancer Medicine, 2020, 9, 6173-6185.	2.8	6
63	Validation of the Prognostic Stage of American Joint Committee on Cancer Eighth Edition Staging Manual in Invasive Lobular Carcinoma Compared to Invasive Ductal Carcinoma and Proposal of a Novel Score System. Frontiers in Oncology, 2020, 10, 1471.	2.8	6
64	CRISPR-cas9 Screening Identified Lethal Genes Enriched in Cell Cycle Pathway and of Prognosis Significance in Breast Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 646774.	3.7	6
65	Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer. Journal of Geriatric Oncology, 2020, 11, 843-849.	1.0	5
66	<p>Biomarkers of Insulin and the Insulin-Like Growth Factor Axis in Relation to Breast Cancer Risk in Chinese Women</p>. OncoTargets and Therapy, 2020, Volume 13, 8027-8036.	2.0	5
67	Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients. Frontiers in Oncology, 2021, 11, 619840.	2.8	5
68	A nomogram to predict adjuvant chemotherapy recommendation in breast cancer patients with intermediate recurrence score. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 222-230.	2.2	5
69	Comparison of the Distribution Pattern of 21-Gene Recurrence Score between Mucinous Breast Cancer and Infiltrating Ductal Carcinoma in Chinese Population: A Retrospective Single-Center Study. Cancer Research and Treatment, 2020, 52, 671-679.	3.0	5
70	Long noncoding RNA HOXC-AS3 indicates a poor prognosis and regulates tumorigenesis by binding to YBX1 in breast cancer. American Journal of Translational Research (discontinued), 2020, 12, 6335-6350.	0.0	5
71	Molecular Subtype May Be More Associated With Prognosis and Chemotherapy Benefit Than Tumor Size in T1N0 Breast Cancer Patients: An Analysis of 2,168 Patients for Possible De-Escalation Treatment. Frontiers in Oncology, 2021, 11, 636266.	2.8	4
72	Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. Breast Cancer Research and Treatment, 2021, 187, 759-768.	2.5	4

#	ARTICLE	IF	CITATIONS
73	Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30. <i>Oncology Letters</i> , 2020, 20, 1545-1556.	1.8	4
74	Association of Obesity and Luminal Subtypes in Prognosis and Adjuvant Endocrine Treatment Effectiveness Prediction in Chinese Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2022, 12, .	2.8	4
75	Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1315.	2.8	3
76	A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age. <i>Journal of Translational Medicine</i> , 2021, 19, 75.	4.4	3
77	Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis. <i>Cancer Management and Research</i> , 2021, Volume 13, 6279-6289.	1.9	3
78	Association of epithelial-mesenchymal transition with lapatinib resistance through multiple pathways activation in HER2-positive breast cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, e11579-e11579.	1.6	3
79	Prognostic Factors and Surgery for Breast Cancer Patients With Locoregional Recurrence: An Analysis of 5,202 Consecutive Patients. <i>Frontiers in Oncology</i> , 2021, 11, 763119.	2.8	3
80	A Multi-disciplinary Medical Treatment Decision Support System with intelligent treatment recommendation. , 2016, , .		2
81	A Novel Prognostic Scoring System Integrating Gene Expressions and Clinicopathological Characteristics to Predict Very Early Relapse in Node-Negative Estrogen Receptor-Positive/HER2-Negative Breast Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 1335.	2.8	2
82	Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 708.	2.8	2
83	Comprehensive analysis of the 21-gene recurrence score in invasive ductal breast carcinoma with or without ductal carcinoma in situ component. <i>British Journal of Cancer</i> , 2021, 124, 975-981.	6.4	2
84	21-Gene Recurrence Assay Associated With Favorable Metabolic Profiles in HR-Positive, HER2-Negative Early-Stage Breast Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 725161.	3.5	2
85	Predictors of Nodal Pathological Complete Response in Asian Women with Stage II-III Node-Positive Breast Cancer. <i>Oncology</i> , 2021, 99, 359-364.	1.9	2
86	Impact of Different Modules of 21-Gene Assay in Early Breast Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 759338.	3.5	2
87	Pathological underestimation and biomarkers concordance rates in breast cancer patients diagnosed with ductal carcinoma in situ at preoperative biopsy. <i>Scientific Reports</i> , 2022, 12, 2169.	3.3	2
88	Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1-2N0M0, Estrogen Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Invasive Breast Cancer: A Population-Based Analysis. <i>Oncologist</i> , 2019, 24, e1014-e1023.	3.7	1
89	Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score. <i>Journal of Cancer</i> , 2020, 11, 2509-2517.	2.5	1
90	Identification of Ten Mitosis Genes Associated with Tamoxifen Resistance in Breast Cancer. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 3611-3624.	2.0	1

#	ARTICLE	IF	CITATIONS
91	Combined Estrogen Receptor and Progesterone Receptor Level Can Predict Survival Outcome in Human Epidermal Growth Factor Receptor 2-positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, 22, e147-e156.	2.4	1
92	Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. <i>BMC Cancer</i> , 2021, 21, 707.	2.6	1
93	Clinical characteristics and disease outcomes in ER+ breast cancer: a comparison between HER2+ patients treated with trastuzumab and HER2- patients. <i>BMC Cancer</i> , 2021, 21, 807.	2.6	1
94	Effect of curcumin on lapatinib sensitivity and lapatinib resistance associated EMT and stem-like phenotype in HER2 positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e11594-e11594.	1.6	1
95	ASO Author Reflections: Core Needle Biopsy and Hormonal Receptor Retesting in Breast Cancer: Controversy and Management. <i>Annals of Surgical Oncology</i> , 2020, 27, 731-732.	1.5	0
96	Factors Influencing Adjuvant Chemotherapy and Trastuzumab Choice in Older Human Epidermal Growth Factor Receptor 2-positive Breast Cancer Patients. <i>Journal of Cancer</i> , 2020, 11, 2602-2609.	2.5	0
97	Abstract PS17-38: Comprehensive association analysis of 21-gene recurrence score and overweight in breast cancer patients. , 2021, , .		0
98	Abstract PS4-28: Efficacy of adjuvant chemotherapy stratified by age and the 21 gene recurrence score in estrogen receptor positive breast cancer. , 2021, , .		0
99	Effect of cancer-associated fibroblasts on trastuzumab resistance by activating multiple pathways in HER2-positive breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, e11587-e11587.	1.6	0
100	Analysis of factors related to adjuvant chemotherapy decision in early breast cancer patients with intermediate recurrence score.. <i>Journal of Clinical Oncology</i> , 2017, 35, e12032-e12032.	1.6	0
101	Quantitative measurement of total erbB2 (H2T), p110 t-erbB2, and erbB2:erbB3 (H23D) heterodimer expression and p110 t-erbB2 in malignant progression from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 12089-12089.	1.6	0
102	Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.. <i>American Journal of Cancer Research</i> , 2021, 11, 6188-6199.	1.4	0
103	Association of machine learning ultrasound radiomics and disease outcome in triple negative breast cancer.. <i>American Journal of Cancer Research</i> , 2022, 12, 152-164.	1.4	0